Terumo Corp

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.

Terumo Corporation (OTCPK:TRUMF) Q4 2021 Earnings Conference Call May 13, 2022 7:00 AM ET Company Participants Naoki Muto - Chief Accounting and Financial Officer Shinjiro Sato - President and CEO Conference Call Participants Operator I am the CFO, Muto. I will now explain the results for the fiscal year ending March 2022.

Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q4 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) Q3 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q2 2022 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) Q1 2022 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) Management on Q3 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) CEO Naoki Muto on Q1 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q4 2020 Results - Earnings Call Transcript

Marker Therapeutics Inc

The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.

FDA grants emergency authorization to two blood purification systems

News for Terumo Corp Stock (TRUMY)